Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy.

Diabetic nephropathy (DN) is one of the most common and important microvascular complications of diabetes mellitus (DM). The main clinical features of DN are proteinuria and a progressive decline in renal function , which are associated with structural and functional changes in the kidney. The pathogenesis of DN is multifactorial, including genetic, metabolic and haemodynamic factors, which can trigger a sequence of events. Controlling metabolic risks such as hyperglycaemia, hypertension and dyslipidaemia is not enough to slow the progression of DN. Recent studies have emphasized immunoinflammation as a critical pathogenic factor in the progression of DN. Therefore, targeting inflammation is considered a potential and novel treatment strategy for DN. In this review, we will briefly introduce the inflammatory process of DN and discuss the anti-inflammatory effects of antidiabetic drugs when treating DN.

• Publication year

  2019

• Venue

  Current Medicinal Chemistry

• Publication date

  2019-11-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/0929867326666191108160643PMID 31701843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Glimpse of the Mechanisms Related to Renal Fibrosis in Diabetic Nephropathy.

  2019cited by this paper
• The effects of vitamin D3 supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial.

  2019cited by this paper
• Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism.

  2019cited by this paper
• Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases

  2018cited by this paper
• IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

  2018cited by this paper
• Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes

  2018cited by this paper
• The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin

  2018cited by this paper
• Effects of sodium glucose co-transporter 2 inhibitors on the kidney

  2018cited by this paper
• [Protective effect of simvastatin on kidney of rats with diabetes mellitus and the possible mechanism].

  2018cited by this paper
• Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

  2017cited by this paper
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

  2017cited by this paper
• Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy.

  2017cited by this paper
• Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.

  2017cited by this paper
• Diabetic nephropathy - is this an immune disorder?

  2017cited by this paper
• Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation

  2017cited by this paper
• Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.

  2017cited by this paper
• SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

  2017cited by this paper
• Atrasentan for the treatment of diabetic nephropathy

  2017cited by this paper
• A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

  2017cited by this paper
• Normoalbuminuric diabetic kidney disease

  2017cited by this paper
• Non-genetic mechanisms of diabetic nephropathy

  2017cited by this paper
• Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.

  2017cited by this paper
• SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy

  2017cited by this paper
• Nephroprotective Effects of Metformin in Diabetic Nephropathy

  2017cited by this paper
• Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.

  2017cited by this paper
• Liraglutide mitigates TNF‐α induced pro‐atherogenic changes and microvesicle release in HUVEC from diabetic women

  2017cited by this paper
• Macrophages in diabetic nephropathy in patients with type 2 diabetes

  2016cited by this paper
• Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study

  2016cited by this paper
• Diabetes medications: Impact on inflammation and wound healing.

  2016cited by this paper
• Renoprotective effect of atorvastatin on STZ-diabetic rats through inhibiting inflammatory factors expression in diabetic rat.

  2016cited by this paper
• In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway

  2016cited by this paper
• The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.

  2016cited by this paper
• Glucagon‐like peptide‐1 and vitamin D: anti‐inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells

  2016cited by this paper
• Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?

  2016cited by this paper
• Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence

  2016cited by this paper
• Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation

  2016cited by this paper
• Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

  2016cited by this paper
• Endothelin

  2016cited by this paper
• Cut to the chase: a review of CD26/dipeptidyl peptidase‐4's (DPP4) entanglement in the immune system

  2016cited by this paper
• An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

  2016cited by this paper
• Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

  2015cited by this paper
• Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

  2015cited by this paper
• Immune Cells and Inflammation in Diabetic Nephropathy

  2015cited by this paper
• Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

  2015cited by this paper
• Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?

  2015cited by this paper
• Phosphodiesterase type 5 inhibitors and kidney disease

  2015cited by this paper
• Renoprotective effects of incretin‐based drugs: A novel pleiotropic effect of dipeptidyl peptidase‐4 inhibitor

  2015cited by this paper
• Endothelin‐receptor antagonists for diabetic nephropathy: A meta‐analysis

  2015cited by this paper
• Endothelin Receptor Antagonists: New Hope for Renal Protection?

  2015cited by this paper
• RELEVANCE OF TNF-α IN THE CONTEXT OF OTHER INFLAMMATORY CYTOKINES IN THE PROGRESSION OF DIABETIC NEPHROPATHY

  2015cited by this paper
• Pleiotropic Benefits of Metformin: Macrophage Targeting Its Anti-inflammatory Mechanisms

  2015cited by this paper
• Vitamin D & its analogues in type 2 diabetic nephropathy: a systematic review

  2015cited by this paper
• Inflammatory Cytokines in Diabetic Nephropathy

  2015cited by this paper
• US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States.

  2015cited by this paper
• Metformin prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.

  2015cited by this paper
• Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase

  2015cited by this paper
• A review of gliptins for 2014

  2015cited by this paper
• Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents

  2015cited by this paper
• Pharmacological effects of vitamin D and its analogs: recent developments.

  2014cited by this paper
• Lipid‐lowering treatment and inflammatory mediators in diabetes and chronic kidney disease

  2014cited by this paper
• Calcitriol plays a protective role in diabetic nephropathy through anti-inflammatory effects.

  2014cited by this paper
• Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

  2014cited by this paper
• Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.

  2014cited by this paper
• Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients.

  2014cited by this paper
• Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats

  2014cited by this paper
• Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.

  2014cited by this paper
• Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice

  2014cited by this paper
• Metformin Inhibits Monocyte-to-Macrophage Differentiation via AMPK-Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis

  2014cited by this paper
• Endothelin and Endothelin Antagonists in Chronic Kidney Disease

  2014cited by this paper
• Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

  2014cited by this paper
• Association between serum level of vitamin D and lipid profiles in type 2 diabetic patients in Iran

  2014cited by this paper
• Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals

  2014cited by this paper
• Metformin: Current knowledge

  2014cited by this paper
• Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway.

  2014cited by this paper
• The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.

  2014cited by this paper
• A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy

  2014cited by this paper
• β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

  2014cited by this paper
• SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

  2014cited by this paper
• Experimental comparison of protective characteristics of enalapril and trimetazidine in diabetic nephropathy

  2014cited by this paper
• Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.

  2013cited by this paper
• Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1.

  2013cited by this paper
• [The association between vitamin D deficiency and diabetic nephropathy in type 2 diabetic patients].

  2013cited by this paper
• Bright renoprotective properties of metformin: beyond blood glucose regulatory effects.

  2013cited by this paper
• The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.

  2013cited by this paper
• Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Diabetic kidney disease and immune modulation.

  2013cited by this paper
• Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

  2013cited by this paper
• Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects.

  2013cited by this paper
• Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.

  2012cited by this paper
• Inflammation in Diabetic Nephropathy

  2012cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2012cited by this paper
• GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.

  2012cited by this paper
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

  2012cited by this paper
• Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?

  2012cited by this paper
• Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.

  2012cited by this paper
• Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

  2012cited by this paper

• A mathematical model of glomerular fibrosis in diabetic kidney disease to predict therapeutic efficacy

  2024cites this paper
• Dendrobium mixture attenuates renal damage in rats with diabetic nephropathy by inhibiting the PI3K/Akt/mTOR pathway

  2021cites this paper
• Macrophage Activation Syndrome and COVID 19: Impact of MAPK Driven Immune-Epigenetic Programming by SARS-Cov-2

  2021cites this paper
• Benzimidazole‐based fluorophores for the detection of amyloid fibrils with higher sensitivity than Thioflavin‐T

  2020cites this paper
• ISREA: An Efficient Peak-Preserving Baseline Correction Algorithm for Raman Spectra

  2020cites this paper
• Small-molecule CSF1R kinase inhibitors; review of patents 2015-present

  2020cites this paper
• Potential monoamine oxidase A inhibitor suppressing paclitaxel‐resistant non‐small cell lung cancer metastasis and growth

  2020cites this paper
• Machine learning approaches and databases for prediction of drug–target interaction: a survey paper

  2020cites this paper
• Nanomaterials for radiotherapeutics-based multimodal synergistic cancer therapy

  2020cites this paper
• Progress of individualized chemotherapy for gastric carcinoma under the guidance of genetic testing.

  2019cites this paper
• Recent insights into natural product inhibitors of matrix metalloproteinases.

  2019cites this paper
• Two New Cytotoxic Compounds from a Deep-Sea Penicillum citreonigrum XT20-134

  2019cites this paper